Ghulam Mohammad

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5467415/publications.pdf

Version: 2024-02-01

62 papers

2,304 citations

218592 26 h-index 243529 44 g-index

63 all docs

63 docs citations

63 times ranked

2591 citing authors

#	Article	IF	CITATIONS
1	Epigenetic modifications in diabetes. Metabolism: Clinical and Experimental, 2022, 126, 154920.	1.5	26
2	Mitochondrial Fragmentation in a High Homocysteine Environment in Diabetic Retinopathy. Antioxidants, 2022, $11,365$.	2.2	8
3	Mitochondrial Dynamics in the Metabolic Memory of Diabetic Retinopathy. Journal of Diabetes Research, 2022, 2022, 1-14.	1.0	12
4	Involvement of High Mobility Group Box 1 Protein in Optic Nerve Damage in Diabetes. Eye and Brain, 2022, Volume 14, 59-69.	3.8	0
5	Regulation of Rac1 transcription by histone and DNA methylation in diabetic retinopathy. Scientific Reports, 2021, 11, 14097.	1.6	15
6	Nuclear Genome-Encoded Long Noncoding RNAs and Mitochondrial Damage in Diabetic Retinopathy. Cells, 2021, 10, 3271.	1.8	19
7	Homocysteine Disrupts Balance between MMP-9 and Its Tissue Inhibitor in Diabetic Retinopathy: The Role of DNA Methylation. International Journal of Molecular Sciences, 2020, 21, 1771.	1.8	25
8	Faulty homocysteine recycling in diabetic retinopathy. Eye and Vision (London, England), 2020, 7, 4.	1.4	27
9	Epigenetics and Mitochondrial Stability in the Metabolic Memory Phenomenon Associated with Continued Progression of Diabetic Retinopathy. Scientific Reports, 2020, 10, 6655.	1.6	36
10	Hydrogen Sulfide: A Potential Therapeutic Target in the Development of Diabetic Retinopathy. , 2020, 61, 35.		16
11	Functional Regulation of an Oxidative Stress Mediator, Rac1, in Diabetic Retinopathy. Molecular Neurobiology, 2019, 56, 8643-8655.	1.9	28
12	Epigenetic Modifications Compromise Mitochondrial DNA Quality Control in the Development of Diabetic Retinopathy., 2019, 60, 3943.		27
13	Cross-Talk between Sirtuin 1 and the Proinflammatory Mediator High-Mobility Group Box-1 in the Regulation of Blood-Retinal Barrier Breakdown in Diabetic Retinopathy. Current Eye Research, 2019, 44, 1133-1143.	0.7	18
14	Mitochondrial fusion and maintenance of mitochondrial homeostasis in diabetic retinopathy. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1617-1626.	1.8	67
15	Myeloid-Related Protein-14/MRP-14/S100A9/Calgranulin B is Associated with Inflammation in Proliferative Diabetic Retinopathy. Ocular Immunology and Inflammation, 2018, 26, 1-10.	1.0	14
16	Differential expression and localization of human tissue inhibitors of metalloproteinases in proliferative diabetic retinopathy. Acta Ophthalmologica, 2018, 96, e27-e37.	0.6	22
17	Unbalanced Vitreous Levels of Osteoprotegerin, RANKL, RANK, and TRAIL in Proliferative Diabetic Retinopathy. Ocular Immunology and Inflammation, 2018, 26, 1248-1260.	1.0	9
18	Association of 150â€kDa oxygenâ€regulated protein with vascular endothelial growth factor in proliferative diabetic retinopathy. Acta Ophthalmologica, 2018, 96, e460-e467.	0.6	7

#	Article	IF	CITATIONS
19	The Poly(ADP-Ribose)Polymerase-1 Inhibitor 1,5-Isoquinolinediol Attenuate Diabetes-Induced NADPH Oxidase-Derived Oxidative Stress in Retina. Journal of Ocular Pharmacology and Therapeutics, 2018, 34, 512-520.	0.6	9
20	Matrix metalloproteinase-14 is a biomarker of angiogenic activity in proliferative diabetic retinopathy. Molecular Vision, 2018, 24, 394-406.	1.1	20
21	Rho-Associated Protein Kinase-1 Mediates the Regulation of Inflammatory Markers in Diabetic Retina and in Retinal Mýller Cells. Annals of Clinical and Laboratory Science, 2018, 48, 137-145.	0.2	7
22	Extracellular matrix metalloproteinase inducer (<scp>EMMPRIN</scp>) is a potential biomarker of angiogenesis in proliferative diabetic retinopathy. Acta Ophthalmologica, 2017, 95, 697-704.	0.6	17
23	High-Mobility Group Box-1 Protein Mediates the Regulation of Signal Transducer and Activator of Transcription-3 in the Diabetic Retina and in Human Retinal Mýller Cells. Ophthalmic Research, 2017, 57, 150-160.	1.0	13
24	Osteoprotegerin Is a New Regulator of Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy., 2017, 58, 3189.		30
25	Association of HMGB1 with oxidative stress markers and regulators in PDR. Molecular Vision, 2017, 23, 853-871.	1.1	25
26	Upregulation of Thrombin/Matrix Metalloproteinase-1/Protease-Activated Receptor-1 Chain in Proliferative Diabetic Retinopathy. Current Eye Research, 2016, 41, 1590-1600.	0.7	26
27	Coexpression of heparanase activity, cathepsin L, tissue factor, tissue factor pathway inhibitor, and MMP-9 in proliferative diabetic retinopathy. Molecular Vision, 2016, 22, 424-35.	1.1	15
28	Upregulated Expression of Heparanase in the Vitreous of Patients With Proliferative Diabetic Retinopathy Originates From Activated Endothelial Cells and Leukocytes., 2015, 56, 8239.		33
29	The Tumor Necrosis Factor Superfamily Members TWEAK, TNFSF15 and Fibroblast Growth Factor-Inducible Protein 14 Are Upregulated in Proliferative Diabetic Retinopathy. Ophthalmic Research, 2015, 53, 122-130.	1.0	14
30	High-Mobility Group Box-1 Modulates the Expression of Inflammatory and Angiogenic Signaling Pathways in Diabetic Retina. Current Eye Research, 2015, 40, 1141-1152.	0.7	33
31	The Angiogenic Biomarker Endocan is Upregulated in Proliferative Diabetic Retinopathy and Correlates with Vascular Endothelial Growth Factor. Current Eye Research, 2015, 40, 321-331.	0.7	30
32	The Chemokine Platelet Factor-4 Variant (PF-4var)/CXCL4L1 Inhibits Diabetes-Induced Blood–Retinal Barrier Breakdown., 2015, 56, 1956.		14
33	Mutual enhancement between high-mobility group box-1 and NADPH oxidase-derived reactive oxygen species mediates diabetes-induced upregulation of retinal apoptotic markers. Journal of Physiology and Biochemistry, 2015, 71, 359-372.	1.3	52
34	Role of high-mobility group box-1 protein in disruption of vascular barriers and regulation of leukocyte–endothelial interactions. Journal of Receptor and Signal Transduction Research, 2015, 35, 340-345.	1.3	23
35	Tiam1-Rac1 Axis Promotes Activation of p38 MAP Kinase in the Development of Diabetic Retinopathy: Evidence for a Requisite Role for Protein Palmitoylation. Cellular Physiology and Biochemistry, 2015, 36, 208-220.	1.1	45
36	Cellular Mechanisms of High Mobility Group 1 (HMGB-1) Protein Action in the Diabetic Retinopathy. PLoS ONE, 2014, 9, e87574.	1.1	29

#	Article	IF	Citations
37	Expression of bioactive lysophospholipids and processing enzymes in the vitreous from patients with proliferative diabetic retinopathy. Lipids in Health and Disease, 2014, 13, 187.	1.2	20
38	The Proinflammatory Cytokine High-Mobility Group Box-1 Mediates Retinal Neuropathy Induced by Diabetes. Mediators of Inflammation, 2014, 2014, 1-10.	1.4	42
39	TIAM1–RAC1 signalling axis-mediated activation of NADPH oxidase-2 initiates mitochondrial damage in the development of diabetic retinopathy. Diabetologia, 2014, 57, 1047-1056.	2.9	114
40	Functional links between gelatinase B/matrix metalloproteinase-9 and prominin-1/CD133 in diabetic retinal vasculopathy and neuropathy. Progress in Retinal and Eye Research, 2014, 43, 76-91.	7.3	19
41	S100A4 is upregulated in proliferative diabetic retinopathy and correlates with markers of angiogenesis and fibrogenesis. Molecular Vision, 2014, 20, 1209-24.	1.1	37
42	Expression of lysophosphatidic acid, autotaxin and acylglycerol kinase as biomarkers in diabetic retinopathy. Acta Diabetologica, 2013, 50, 363-371.	1.2	34
43	Autocrine CCL2, CXCL4, CXCL9 and CXCL10 signal in retinal endothelial cells and are enhanced in diabetic retinopathy. Experimental Eye Research, 2013, 109, 67-76.	1.2	74
44	High-mobility group box-1 protein activates inflammatory signaling pathway components and disrupts retinal vascular-barrier in the diabetic retina. Experimental Eye Research, 2013, 107, 101-109.	1.2	75
45	High-Mobility Group Box-1 Induces Decreased Brain-Derived Neurotrophic Factor-Mediated Neuroprotection in the Diabetic Retina. Mediators of Inflammation, 2013, 2013, 1-11.	1.4	29
46	Poly (ADP-Ribose) Polymerase Mediates Diabetes-Induced Retinal Neuropathy. Mediators of Inflammation, 2013, 2013, 1-10.	1.4	31
47	New Developments in the Pathophysiology and Management of Diabetic Retinopathy. Journal of Diabetes Research, 2013, 2013, 1-2. The <mml:math <="" td="" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td>1.0</td><td>16</td></mml:math>	1.0	16
48	id="M1"> <mml:mrow><mml:msub><mml:mrow><mml:mtext>ERK</mml:mtext></mml:mrow><mml:mrow><mml:mrow><mml:mnl:mnl:mnl:mnl:mnl:mnl:mnl:mnl:mnl:< td=""><td>nl:mn 1.0</td><td>23</td></mml:mnl:mnl:mnl:mnl:mnl:mnl:mnl:mnl:mnl:<></mml:mrow></mml:mrow></mml:msub></mml:mrow>	nl:mn 1.0	23
49	Retina. Journal of Diabetes Research, 2013, 2013, 1-9. Neurotrophins and Neurotrophin Receptors in Proliferative Diabetic Retinopathy. PLoS ONE, 2013, 8, e65472.	1.1	36
50	Relationship between Vitreous Levels of Matrix Metalloproteinases and Vascular Endothelial Growth Factor in Proliferative Diabetic Retinopathy. PLoS ONE, 2013, 8, e85857.	1.1	70
51	High-Mobility Group Box-1 and Endothelial Cell Angiogenic Markers in the Vitreous from Patients with Proliferative Diabetic Retinopathy. Mediators of Inflammation, 2012, 2012, 1-7.	1.4	34
52	Role of matrix metalloproteinase-2 and -9 in the development of diabetic retinopathy. Journal of Ocular Biology, Diseases, and Informatics, 2012, 5, 1-8.	0.2	34
53	Diabetic retinopathy and signaling mechanism for activation of matrix metalloproteinaseâ€9. Journal of Cellular Physiology, 2012, 227, 1052-1061.	2.0	70
54	Novel Role of Mitochondrial Matrix Metalloproteinase-2 in the Development of Diabetic Retinopathy., 2011, 52, 3832.		76

#	Article	IF	CITATION
55	Diabetic Retinopathy, Superoxide Damage and Antioxidants. Current Pharmaceutical Biotechnology, 2011, 12, 352-361.	0.9	86
56	Abrogation of <i>MMP-9</i> Gene Protects Against the Development of Retinopathy in Diabetic Mice by Preventing Mitochondrial Damage. Diabetes, 2011, 60, 3023-3033.	0.3	131
57	Interleukin- $\hat{\Pi}^2$ and mitochondria damage, and the development of diabetic retinopathy. Journal of Ocular Biology, Diseases, and Informatics, 2011, 4, 3-9.	0.2	22
58	The role of Raf-1 kinase in diabetic retinopathy. Expert Opinion on Therapeutic Targets, 2011, 15, 357-364.	1.5	14
59	Matrix metalloproteinase-2 in the development of diabetic retinopathy and mitochondrial dysfunction. Laboratory Investigation, 2010, 90, 1365-1372.	1.7	85
60	Glyceraldehyde-3-Phosphate Dehydrogenase in Retinal Microvasculature: Implications for the Development and Progression of Diabetic Retinopathy., 2010, 51, 1765.		37
61	Role of Mitochondrial DNA Damage in the Development of Diabetic Retinopathy, and the Metabolic Memory Phenomenon Associated with Its Progression. Antioxidants and Redox Signaling, 2010, 13, 797-805.	2.5	152
62	Oxidative damage of mitochondrial DNA in diabetes and its protection by manganese superoxide dismutase. Free Radical Research, 2010, 44, 313-321.	1.5	129